Prestige Consumer Healthcare (PBH) Income from Non-Controlling Interests (2020)
Prestige Consumer Healthcare (PBH) posted quarterly Income from Non-Controlling Interests of $1.1 million for Q4 2020, up 6.9% quarter-over-quarter from $985000.0 in Q3 2020.
Prestige Consumer Healthcare (PBH) Income from Non-Controlling Interests (2020) Analysis & Trends
Prestige Consumer Healthcare's Income from Non-Controlling Interests history runs 1 years deep, the most recent figure standing at $1.1 million for Q4 2020.
- In Q4 2020, Income from Non-Controlling Interests changed N/A year-over-year to $1.1 million; the TTM figure through Dec 2020 stood at -$2.5 million (changed N/A YoY), while the FY2020 annual figure was -$4.9 million, changed N/A from the prior year.
- Income from Non-Controlling Interests for Q4 2020 stood at $1.1 million, up from $985000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $1.1 million in Q4 2020, with the low at -$4.9 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Prestige Consumer Healthcare | 2.43 Bn | 2.37 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 1.05 Mn |
| Sep 30, 2020 | 985,000.00 |
| Jun 30, 2020 | 309,000.00 |
| Mar 31, 2020 | -4.86 Mn |